Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

A new clinical trial suggests that once-weekly semaglutide may reduce alcohol consumption and cravings in adults with alcohol use disorder.

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.